Overview of the proto-oncogene KRAS including KRAS gene mutations and its role as a biomarker in metastatic colorectal cancer

Areas of discussion include What is the field of companion diagnostics, Companion Diagnostics for Cancer (K-Ras mutation testing), and Companion Diagnostics for Drug metabolism (CYP450 mutation testing). Speaker: Art Braden, Ph.D., Roche Diagnostics

Hypercoagulation disorders are associated with an increased risk of blood clot (thrombus) formation. Factor V Leiden is the most common hereditary blood coagulation disorder in the United States, present in 5% of the Caucasian population and approximately 1.2% of the African American population. Prothrombin is the second most inherited clotting abnormality present in approximately 2% of the general population. Speaker: Denise Heaney, Ph.D., Roche Diagnostics

A clinical overview of the epidemiology and disease state of melanoma. Also this presentation focuses on the clinical implementation of mutations in the signaling protein BRAF